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Abstract 
Background: The aim of this systematic review is to provide an overview of the 
diagnosis, treatment options and treatment related complications of cervical esophageal 
carcinoma (CEC) and subsequently provide recommendations to improve quality of 
care. 
Design: Studies were identified in PubMed, EMBASE and Web of Science. A total of 
107 publications fulfilled the inclusion criteria and were included.  
Results: CEC is uncommon, accounting for 2-10% of all esophageal carcinomas. These 
tumors are often locally advanced at presentation and have a poor prognosis, with a 5-
year overall survival (OS) of 30%. Tobacco and alcohol consumption seem to be the 
major risk factors for developing CEC. Surgery is usually not possible due to the very 
close relationship to other organs such as the larynx, trachea and thyroid gland. 
Therefore, the current standard of care is definitive chemoradiation (dCRT) with curative 
intent. Treatment regimens used to treat CEC are adapted by established regimens in 
lower esophageal squamous cell carcinoma (SCC) and head and neck squamous cell 
carcinoma (HNSCC). However, dCRT may be accompanied by severe side effects and 
complications. Several diagnostic and predictive markers have been studied, but 
currently there is no other biomarker than clinical stage to determine patient 
management.  
Suggestions to improve patient outcomes are to determine the exact radiation dose 
needed for adequate locoregional control and to combine radiotherapy (RT) with optimal 
systemic therapy backbone.  
Conclusion: CEC remains unchartered territory for many practising physicians and 
patient with CEC have a poor prognosis. In order to improve the outcome for CEC 
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patients, future studies should focus on identification of new diagnostic biomarkers or 
targets for radiosensitizers, amelioration of radiation schedules, optimal combination of 
chemotherapeutic agents and/or new therapeutic targets.  
 
Key words: cervical esophageal cancer, chemoradiation, targeted therapy, toxicity, 
survival, review.  
 
Key Message: "Cervical esophageal squamous cell carcinomas are rare and guidelines are inconclusive 
regarding treatment of these tumors. Taking survival data and toxicity profiles in consideration, the 
optimal treatment for cervical esophageal cancer patients is not yet defined." 
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Introduction 
 
The cervical esophagus is the short part of the esophagus between the lower border of 
the cricoid cartilage and the thoracic inlet (suprasternal notch), approximately 18 cm 
from the incisor teeth [1]. Carcinoma of the cervical esophagus (CEC), usually 
squamous cell carcinoma (SCC), is uncommon, with 5 new cases per 1 million person 
years in the United States [2] and accounts for 2-10% of all esophageal carcinomas [3]. 
The highest rates of SCC are found in Eastern Asia and Southern Africa, the lowest 
rates in Western Africa and Central America [4]. Management of CEC differs from that of 
cancers of the lower two thirds of the esophagus, because CECs are often locally 
advanced at time of diagnosis infiltrating nearby anatomical structures including e.g. the 
cricoid, thyroid cartilage or thyroid gland. Moreover, patients with CEC often present with 
lymph node metastases [1]. Most CECs are not treatable by surgery, as this would 
involve mutilating resections including pharyngo-laryngo-esophagectomy (PLE). 
Therefore, definitive chemoradiation (dCRT) is the standard treatment modality 
recommended by the National Comprehensive Cancer Network (NCCN) and European 
Society for Medical Oncology (ESMO) guidelines [5, 6]. Definitive chemoradiation 
usually consists of 50.4 Gy in 1.8 Gy per fraction per day. Higher doses up to 60-66 Gy 
may be appropriate if no surgery is planned. Concurrent chemotherapy generally 
consists of cisplatin and 5-fluorouracil (5-FU), oxaliplatin and 5-FU or carboplatin and 
paclitaxel [5]. As CEC behaves very aggressive, as they grow in an area of abundant 
lymphatic drainage and fail to produce early symptoms, and easily and frequently extend 
towards the hypopharynx, these tumors are sometimes treated with schedules for locally 
advanced head and neck squamous cell carcinomas (LAHNSCC), which consists of 70 
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Gy in 35 fractions and cisplatin 100 mg/m2 on day 1, 22 and 43 of radiotherapy (RT) 
(NCCN guidelines for head and neck cancers [7]). dCRT is related to life-threatening 
adverse events in 5 to 10% of patients [8, 9], thus, further research is needed to define 
the optimal treatment schedule with adequate survival and acceptable toxicity. In this 
literature review, we will provide an overview of the current knowledge and controversies 
surrounding CEC with respect to histopathology, genetic factors, etiology, diagnosis, 
treatment, toxicity and local disease control rate and survival and we will provide 
recommendations for future studies regarding potential curative treatment options, 
based on the current literature.  
 Methods 
 
Literature search strategy 
 
In May 2015, the PubMed, Web of Science and EMBASE databases were searched for 
relevant evidence. The literature search strategy is detailed in Supplementary Data 
section 1. The reference lists from included articles were also searched for additional 
relevant studies.  
 
Study inclusion and exclusion criteria 
 
Language was restricted to English. Articles published during the last three decades 
were selected. Studies were included if they comprised a minimum of five patients 
diagnosed with cancer in the cervical esophagus and treated with curative intent. 
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Studies were excluded if patients had distant metastasis and were treated with palliative 
intent. Studies published as abstracts only were excluded. 
 
Literature search results 
 
The initial search in the three databases yielded 639 articles. Based on reading the titles 
and abstracts, 488 articles were excluded. Using Endnote (Version X6, Thomson 
Reuters) and manual screening, 63 duplicate articles were excluded. Eighty-eight 
original articles and reviews were further screened. Thirty articles were excluded based 
on our predefined exclusion criteria leaving 58 full publications for inclusion in this 
review. During the manual search of the reference lists of the included articles, a further 
49 relevant publications were identified resulting in 107 articles that formed the basis of 
this review (for details see flowchart in Figure S1).  
 
Histopathology and genetic factors 
SCC accounts for 95% of cervical esophageal malignancies [10]. Very little is known 
about SCC precursor lesions and genetic factors predisposing for CEC in particular. The 
malignant transformation to SCC involves basal cell hyperplasia, low- and high-grade 
dysplasia and invasive carcinoma. Squamous dysplasia is a well described histological 
precursor lesion of esophageal SCC [11-14]. Dysplasia is thought to be caused by 
molecular alterations [15]. Early detection of molecular alterations, endoscopic and 
histological features of squamous dysplasia is necessary to identify SCC at an early 
stage [16-19]. Modern endoscopy techniques, like micro-endoscopy, lugol staining and 
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the use of biomarkers have the potential to increase early detection [17-19]. 
Genetic alterations in CEC are currently poorly understood and to the best of our 
knowledge, there are no studies investigating only genetic alterations in carcinomas 
located in the cervical esophagus. Several genes have been shown to be down- or 
upregulated in (pre)malignant lesions of esophageal SCC [11, 20-29]. The most 
common genetic alterations consist of allelic losses at chromosomes 3p, 5q, 9p, 9q, 3q, 
17p, 17q, 18q and mutations of p53, RB1 (retinoblastoma protein), ALDH2 (aldehyde 
dehydrogenase-2 gene), MTHFR (methylene tetrahydrofolate reductase gene), EGR1 
(early growth response gene-1), CCND1 (cyclin D1) and cMYC [30-34]. Recent work by 
the Cancer Genome Atlas Initiative provides comprehensive molecular profiling data of 
squamous cancers of the oesophagus which may also facilitate future research for 
diagnostic and therapeutic molecular targets in CEC [35]. There is an urgent clinical 
need for further research in order to investigate the potential usefulness of genetic and 
protein alterations for early diagnosis of CEC.  
 Etiology and risk factors 
Tobacco and alcohol consumption are well known risk factors for CEC [10, 15, 34, 36].  
Mutations in ADH (alcohol-dehydrogenase) 1B and ALDH-2 , both enzymes involved in 
alcohol metabolism have been related to the occurrence of neoplasia in the upper 
aerodigestive tract [10]. 
The variable geographic incidence of CEC with high-risk regions in Iran, Central Asia, 
Mongolia, Northern China and Eastern Cape South Africa suggests a potential influence 
of nutritional and environmental factors. The role of family history has not been clarified 
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yet [34, 37]. Occupational factors have been difficult to evaluate independently because 
esophageal carcinomas often occur in unqualified workers in industry and agriculture, 
who are often also frequent tobacco and/or alcohol consumers. High exposure to 
polycyclic aromatic hydrocarbons (PAHs) has also been associated with a high risk of 
esophageal cancer [38].  
Studies investigating the potential association between human papilloma virus (HPV) 
infection and CEC incidence have conflicting results. Geographical locations with a high 
incidence of esophageal SCC tend to also have a higher incidence of HPV infection in 
patients with esophageal SCC (more than 10% of esophageal SCC cases are related to 
HPV infection) [39-41]. The main strains involved in esophageal cancer appear to be 
HPV 16 and 18 [40]. 
Diagnosis and staging 
Endoscopy and biopsy are the first choice of examination if a CEC is suspected. 
Recommendations regarding the minimum number of biopsies vary between countries, 
ranging from 1 upto 8 [42]. Endoscopic ultrasonography (EUS) is considered to be the 
best technique to assess depth of tumor infiltration and lymph node status and can be 
combined with fine needle aspiration cytology [3, 43, 44]. 18-Fluorodeoxyglucose-
Positron-Emission-Tomography-Computed-Tomography (18F-FDG-PET CT) is highly 
recommended to detect potential tumor invasion into adjacent structures and lymph 
node or distant metastases [44]. Bronchoscopy, with endobronchial ultrasound and 
biopsy can be used to assess infiltration in adjacent structures e.g. trachea [45]. 
Most CECs are locally advanced at time of diagnosis, with approximately 55% being 
 at U
niversity of Leeds on N
ovem
ber 30, 2016
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
9 
TNM stage III or IV tumors and 27% stage II tumors [1, 46-49]. An overview of the 
current TNM staging can be found in Supplementary Data section 2. 
 Treatment 
Historically, surgery has been the standard treatment for CEC. Mostly, a pharyngo-
laryngo-esophagectomy (PLE) was performed, a procedure which includes the resection 
of the larynx and has a huge impact on quality of life [50]. Nonetheless, during the last 
decades the outcome for patients who underwent surgery for CEC has improved due to 
newly developed surgical strategies, like minimally invasive surgery and the use of 
neoadjuvant (chemo)radiotherapy [51]. Furthermore, reconstruction methods like free 
jejunal graft, gastric pull-up or deltopectoral or pectoralis major myocutaneus flap have 
been introduced [50, 52-62]. Despite these efforts, surgical treatment still has a great 
risk of major complications and a high morbidity and mortality rate [57, 63-68].   
In order to improve survival and quality of life, noninvasive treatment options like 
radiotherapy (RT) and dCRT have been explored. The Radiation Therapy Oncology 
Group (RTOG) compared dCRT versus RT alone for the treatment of patients with 
thoracic esophageal cancer and found that dCRT significantly increased 5-year overall 
survival (OS) compared to RT alone, 26% vs 0% [8]. Although this study only included 
patients with thoracic esophageal cancer, the study results form the basis of the current 
nonsurgical treatment of patients with esophageal cancer, including CEC. An update of 
the original RTOG 85-01 trial by Al-Sarraf et al. [69], reports higher survival rates of 
patients treated with dCRT compared to RT alone in the treatment of locally advanced 
esophageal cancer. Another study performed in patients with cervical and upper thoracic 
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esophageal cancer showed less favorable results than the RTOG study, reporting 5-year 
OS of 18.6% in patients treated with dCRT [70]. Other studies reported a 5-year OS of 
about 30% for CEC patients treated with dCRT [46, 71] which is comparable to OS after 
surgery alone (24% to 47%) [56, 58, 63, 66, 72-74]. In comparison to other SCCs in the 
head- and neck region, 5-year OS of patients with CEC is relatively low [10], while it is 
comparable to 5-year OS in patients with SCC located in other parts of the esophagus, 
which is about 26% [8].  
dCRT may cause high rates of toxicity in CEC patients. Common toxic effects include 
dysphagia, dehydration, mucositis, esophagitis, dermatitis and fatigue. An additional 
side effect of chemotherapy is bone marrow suppression [8, 9, 47-49, 71, 75, 76]. 
Moreover, late toxic effects like strictures and fistulas may occur [48, 71, 77]. 
In the next paragraphs we will describe the currently available organ sparing treatment 
options for locally advanced CEC, which combine RT with chemotherapy. 
Systemic therapy used within concurrent treatment regimens for CEC 
Several chemotherapeutic regimens are used, adapted by established regimens in lower 
esophageal SCC and head and neck squamous cell carcinoma (HNSCC). High-dose 
cisplatin-based chemotherapy, consisting of 100 mg/m2 on day 1, 22 and 43 of RT, is 
currently considered one of the treatment options for patients with CEC based upon 
increased cure rates that were observed with high-dose cisplatin in patients with head 
and neck cancer [7, 46]. However, no difference was seen in OS, disease free survival 
(DFS) or locoregional recurrence free survival (LRFS) comparing CEC patients treated 
with high-dose cisplatin with a concurrent RT dose of 70 Gy versus low-dose cisplatin 
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combined with 5-FU or mitomycin C, concurrently administered with RT schedule of 54 
Gy (Table 1) [46]. 
SCC of the lower esophagus are often treated with a combination of cisplatin and 5-FU 
[78], a key factor in the treatment of gastroesophageal cancer [79]. In CEC, the 
combination of cisplatin and 5-FU has shown acceptable cure and survival rates [9, 46-
48, 71] (see Table 1), but combination therapy can lead to higher toxicity rates when 
compared to cisplatin alone. Bleiberg et al. [80] randomized patients with advanced 
esophageal SCC to either receive cisplatin (100 mg/m2) and continuous 5-FU (1,000 
mg/m2/day) from days 1 to 5 or cisplatin alone (100 mg/m2) and found higher 2-year OS 
rates (18% and 9%, respectively), but also higher toxicity rates in the cisplatin/5-FU 
group (16% treatment related deaths in the cisplatin/5-FU group versus 0% in the 
cisplatin alone group).  
Other chemotherapeutic regimens have been studied with comparable results [81, 82]. 
Conroy et al. [81] studied the role of FOLFOX regimen: 5-FU (bolus 400 mg/m2, 
followed by infusional 5-FU 1600 mg/m2 over 46h) plus leucovorin (200 mg/m2) and 
oxaliplatin (85 mg/m2) in patients with adeno-, squamous cell or adenosquamous 
carcinoma. They compared the FOLFOX regimen with standard cisplatin/5-FU and 
found more treatment related deaths in the cisplatin/5-FU group (4.5% in the cisplatin/5-
FU group versus 0.7% in the FOLFOX group). 3 ±year OS was 19.9% ( 95% CI 10.8 - 
31.0) in the FOLFOX group and 26.9% (95% CI 16.9 ± 37.8) in the cisplatin/5-FU group. 
Ruppert et al. [82] identified carboplatin/paclitaxel-based chemotherapy, a regimen 
already used in SCC of the lower esophagus, as a useful alternative to the cisplatin-
based regimen. Van Hagen et al. [83] studied the role of neoadjuvant carboplatin AUC 2 
 at U
niversity of Leeds on N
ovem
ber 30, 2016
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
12 
and paclitaxel 50 mg/m2 for 5 weeks and concurrent RT (41.4 Gy in 23 fractions), 
followed by surgery in esophageal and esophagogastric junction SCC, adenocarcinoma 
and large-cell undifferentiated carcinoma and found a pathological complete response 
(pCR) in 49% of patients with SCC. There was only one treatment-related death among 
the patients ( N = 171) that were treated with neoadjuvant chemoradiation, which 
indicates the great tolerance of this regimen. 3-year OS in this group was 58%, 
compared to 44% in the group that received surgery alone. Moreover, Blom et al. [84] 
found in patients treated with chemoradiation prior to surgery, that the combination of 
carboplatin/paclitaxel/41.4Gy had a lower percentage of treatment related deaths (1.1% 
versus 4.1%) and a comparable 3-year OS rate (57% versus 61%) compared to the 
cisplatin/5-FU/50.4Gy regimen. Hence, low-dose cisplatin, FOLFOX and 
carboplatin/paclitaxel (especially in combination with a low RT dose of 41.4 Gy) are 
useful alternatives to a high-dose cisplatin-based chemotherapy. 
The role of epidermal growth factor receptor (EGFR), targeting therapy using cetuximab, 
an established radiosensitizer in HNSCC [7], seems to be not that prominent in CEC. 
Based on the results of the SCOPE1 trial, a multicenter phase II/III trial, randomizing 
258 patients between standard dCRT and dCRT combined with cetuximab, the use of 
cetuximab cannot be recommended due to treatment limiting toxicity [85]. Likewise, the 
randomized phase III RTOG 0436 trial which compared OS between patients treated 
with dCRT with or without cetuximab [86], and the COG trial, in which esophageal 
cancer patients who had progressed under chemotherapy were randomly assigned to 
either gefitinib or placebo [87], did not find an improvement in OS when an anti-EGFR 
target was added. This is in contrast to the study by Lorenzen et al. [88] , which was 
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published before the SCOPE1 trial but only included 62 patients. They reported a 75% 
disease control rate in the group randomized to standard chemotherapy combined with 
cetuximab (CET-CF), compared to 57% in the group randomized to standard 
chemotherapy alone (CF). This study also found a difference in survival rates, with a 
median OS of 9.5 and 5.5 months for CET-CF and CF, respectively, and therefore 
concluded that the addition of cetuximab to standard chemotherapy might be a useful 
therapeutic approach in patients with advanced (metastatic) esophageal SCC. Recently, 
the subsequent phase III REAL3 trial had to be closed early due to a lack of efficacy 
[89]. These findings seem to indicate that  the use of cetuximab is not recommended in 
patients with CEC.   
Radiotherapy used within concurrent treatment regimens for CEC 
The standard of care regarding dCRT for patients with esophageal cancer is 50.4 Gy 
with concurrent chemotherapy. In case of CEC, there exists some tendency to increase 
the radiation dose to 60-70 Gy to the primary tumor and approximately 40-45 Gy to 
elective lymph node regions, analogous to the treatment of LAHNSCC [90]. The 
randomized phase III INT-0123/RTOG 94-05 trial investigated the effect of dose 
escalation from 50.4 to 64.8 Gy of radiotherapy combined with chemotherapy in 
esophageal cancer from all anatomical locations [78]. There was no increase in survival 
or local/regional control for the high-dose arm. In CEC, there has been a tendency to  
use higher doses of radiation than the standard of 50.4 Gy, upto 66-70 Gy [9, 47, 48, 55, 
91, 92]. From retrospective studies, there are some indications that higher dose of 
radiation might be associated with improved outcome in esophageal cancer; Zhang et 
al. [93] investigated local disease control and survival rates in patients with stage II-III 
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esophageal cancer either treated with high-dose RT (> 51 Gy) or with low-dose RT (< 51 
Gy) and found a positive correlation between radiation dose and locoregional control 
rate and survival. Comparable results regarding the association between a higher 
radiation dose and survival were published by Sun et al. [94]. On the other hand, Huang 
et al. [46] concluded that when using conventionally fractionated RT (70 Gy) rather than 
hypofractionated RT (54 Gy), the addition of prophylactic nodal RT and a change to 
high-dose cisplatin chemotherapy did not result in improved outcome in CEC patients. 
Currently, the ARTDECO study, in which differences in local tumor control, survival and 
grade 3 and 4 toxicity are measured between patients with inoperable esophageal 
cancer treated with a total RT dose of 61.6 Gy in combination with carboplatin/paclitaxel 
and in patients with similar tumor characteristics treated with a total RT dose of 50.4 Gy 
with the same concurrent chemotherapy regimen, is ongoing [95].   
Administering an adequate RT dose to the tumor is often challenging because of the 
close proximity of the cervical esophagus to vital structures like the spinal cord and 
lungs. Modern RT techniques, like intensity modulated radiation therapy (IMRT) and 
simultaneous integrated boost (SIB), in which the intensity of the radiation can be 
changed during treatment, enable a higher dose to the tumor and a reduced dose to 
adjacent structures. Studies suggest that these techniques may be useful in the 
treatment of CEC [75, 90, 96, 97]. Volume-modulated arc RT (VMAT), a rotational 
radiation treatment technique, allows to deliver a more conformal dose to the tumor and 
improved sparing of nearby organs at risk, providing an alternative CEC treatment option 
[98, 99].  
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No consensus has been reached so far regarding elective lymph node irradiation (ENI). 
According to some authors, the omission of ENI did not have a significant effect on the 
failure rate of non-irradiated lymph nodes and OS, but would delay cervical nodal 
progression [76, 100, 101], while others do recommended elective irradiation of neck 
and upper mediastinal lymph node stations [102-105]. Patients who have not been 
treated with ENI might need salvage treatment more frequently than patients treated 
with ENI. However, the latter group of patients might experience more frequently and 
more severe treatment-related toxicity, because of the larger radiation field [76, 106]. 
There are no guidelines recommending the treatment of  paratracheal lymph nodes 
despite the fact that the lymphatic drainage of the cervical esophagus is primarily to the 
paratracheal nodes and 43% of CEC patients have paratracheal lymph node 
metastases [107, 108].  
 Local disease control rate and survival 
The local disease control rate depends mainly on depth of tumour invasion, lymph node 
status and type of treatment [8, 46, 47, 49, 76, 82]. Locoregional recurrence rates in 
CEC patients treated with dCRT, range from 13.7% to 42% within 0 to 8.7 years [46, 76, 
101] compared to 51% to 74.1% within 0 to 4 years in patients treated with RT alone 
[47, 100] and 15.6% to 48.6% within 0 to 15 years in surgically treated patients [53, 56, 
63, 66].  
Local failure is an important prognostic factor for survival. Uno et al. [49] found that after 
dCRT none of the patients with initial local failure as determined by endoscopic 
examination, survived more than 20 months compared to 2-year and 5-year survival 
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rates of 60% and 40%, respectively, in patients with initial local control. Local 
recurrences can be treated by salvage surgery, which potentially has a high morbidity 
rate, but is the only chance for relatively long-term survival [109]. Otherwise, palliative 
treatment options have to be considered. 
Survival rates of patients with CEC remain poor, due to a delayed diagnosis, poor 
performance status of many patients, particular anatomic characteristics of the viscera 
associated with high malignancy potential, frequent occurence of locoregional and 
distant metastases and 12% to 30% increased risk of synchronous or metachronous 
lesions  [9, 46, 110]. Yamada et al. [47] found that performance status and tumor length 
(< 6 cm or > 6 cm) were factors that were significantly related to survival.  
 Discussion and recommendations 
Cervical esophageal cancer (CEC) is a very rare disease and often locally advanced at 
time of diagnosis resulting in limited locoregional disease control and poor survival. 
Dysplasia is a known precursor lesion of squamous cell carcinoma (SCC) [11-14] and 
can be diagnosed by endoscopic biopsy improving the detection of patients at high risk 
of malignant transformation. Detection of genetic changes could also be an effective 
manner of diagnosing early tumors, but unfortunately the molecular changes in cervical 
esophageal cancer (CEC) and its precursor lesions remain to be clarified.  
Due to the presence of locally advanced disease at time of diagnosis and the cancer 
being close to vital structures like the larynx, upper airway and spinal cord, non-surgical 
management seems to be the current preferred therapeutic option. Our review suggests 
that the best results with respect to locoregional disease control and survival can be 
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achieved with definitive chemoradiation (dCRT), however, at the costs of higher 
incidence of toxicity compared to radiotherapy (RT) alone. Despite the introduction of 
dCRT, survival rates remain relatively low and patients require optimal clinical support to 
retain food intake and exercise in order to maintain good quality of life and to achieve 
best patient outcome [111].  
Several different chemoradiation schedules and techniques have been investigated in 
the past, but no consensus has been reached regarding the optimal treatment for CEC 
patients. High-dose RT (60-70 Gy) and concurrent cisplatin, similar to the established 
treatment regimen in locally advanced head and neck SCC (HNSCC), could be an 
option, however there is no level I evidence to support this approach. Although thoracic 
esophageal SCCs defined by being localized caudal of the suprasternal notch, develop 
only few centimeters distal from cervical SCC, the commonly used dCRT schedule for 
thoracic esophageal SCCs consists of a lower radiation dose (50.4 Gy) combined with 
cisplatin/5-fluorouracil (5-FU), oxaliplatin/5-FU or carboplatin/paclitaxel regimen [6]. A 
possible rationale for the use of a lower radiation dose is the very close proximity of vital 
structures in the mediastinum and the lungs. In the CROSS study on preoperative 
chemoradiation, Van Hagen et al. [83] found a pathological complete response (pCR) of 
49% after neoadjuvant chemoradiation (41.4 Gy and concurrent carboplatin/paclitaxel) 
in esophageal SCC of which 2% were located in the proximal third of the esophagus. 
The study by Blom et al [84] suggests this regimen is as effective as dCRT consisting of 
a RT dose of 50.4 Gy and cisplatin/5-FU, and has a more favourable toxicity profile [84]. 
Therefore, we could hypothesize that the currently used high radiation dose in CEC is 
potentially unnecessary as it does not seem to result in higher complete response (CR) 
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rates and outcome in SCC of the lower esophagus [78]. While the use of a high RT dose 
of 61.6 Gy concurrently with chemotherapy in patients with inoperable/irresectable 
esophageal cancer is currently studied in the ARTDECO study [95], it could also be of 
potential interest to study the effect of lower dose RT in CEC alone, which may be 
accompanied by lower toxicity rates.  
However, high toxicity rates in CEC patients [8, 9] might not only be a result of a high 
radiation dose, but could also be an effect of a relatively large radiation field [106], 
especially when combined with concurrent chemotherapy. A reduction of toxicity rates 
may be expected by applying modern state-of-the-art radiation techniques like IMRT, 
lowering the dose to normal structures. However, the current literature is inconclusive; 
some studies propose that an irradiation volume covering the gross volume only is 
appropiate and accompanied with lower toxicity rates [76, 100], while others recommend 
consideration of ENI, especially in case of nodal stage N1 and higher [5, 101]. Given the 
reported incidence of metastases in surrounding lymph nodes (approximately 50% of all 
CECs), especially in the neck (levels II, III and the supraclavicular lymph nodes) and 
upper mediastinum [104, 107], we recommend that ENI of cervical, supraclavicular and 
paratracheal lymph nodes should be considered in CEC invading the hypopharynx. In 
more distally located CEC, which are located close to the suprasternal notch, ENI of 
mediastinal and paratracheal lymph nodes should be considered [105]. We anticipate 
that radiation techniques will improve in the near future enabling the discovery and use 
of newer techniques (e.g. dose painting, in which a non-uniform radiation dose 
distribution is applied to the target volume based on functional or molecular imaging), 
where only the radiation dose needed for adequate locoregional disease control is 
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applied, hopefully minimizing the rate of adverse events.  
With respect to systemic therapy, a cisplatin-based schedule is currently often used, 
since this has shown to be effective in the treatment of HNSCC. Current guidelines are 
inconclusive regarding the most adequate chemotherapy treatment regimen and 
cisplatin/5-FU, oxaliplatin/5-FU or carboplatin/paclitaxel are equally recommended [5]. 
Since the combination of carboplatin and paclitaxel is proven to be effective with 
acceptable adverse event rates in the (neoadjuvant) treatment of lower esophageal SCC 
[82, 83], future studies might want to compare the combination of carboplatin/paclitaxel 
to current cisplatin-based schedules. When molecular profiles of CEC including driver 
oncogenes and potential therapeutic targets will become apparent, the use of targeted 
agents, e.g. as radiosensitizers, might become worthwhile to investigate in future clinical 
trials.  
Furthermore, future research should focus on identifying a dCRT design with adequate 
survival and acceptable toxicity rates. It is of clinical interest to establish whether CECs 
are best treated with head and neck cancer protocols or regimens established in lower 
esophageal SCC. As patients with CECs treated according to the head and neck cancer 
protocol have a worse prognosis compared to patients with HNSCC [72, 74, 108], it 
could be interesting to study the potential underlying molecular differences between 
these two types SCCs. 
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 Conclusion 
Cervical esophageal cancer remains unchartered territory for many practising 
physicians. Treatment of cancers at this site is often difficult because of the cervical 
location and most tumors are locally advanced with invasion of surrounding vital 
structures. To improve survival outcome and reduce morbidity and mortality rates, future 
studies should focus on earlier detection of these cancers and improving treatment 
design by investigating innovative radiation schedules and identifying the optimal 
backbone of systemic therapy.  
Recommendations 
x Future studies that focus on early detection of cervical esophageal carcinoma 
(CEC) precancerous conditions, molecular changes and on identification of 
biomarkers for detection of early disease or as targets for radiosensitizers would 
be desirable for the future. However, since CEC is rare in Western countries, it is 
improbable that screening will impact on this disease outside high-risk areas. 
x Taking the survival data and toxicity profiles of the different dCRT regimens in 
consideration, the optimal treatment regimen for CEC patients is not yet defined.  
x Future studies should focus on whether CEC is best treated according to a head 
and neck cancer or esophageal cancer protocol. 
x We recommend that ENI of cervical, supraclavicular and paratracheal lymph 
nodes should be considered. 
x Finally, one should be aware that patients will need optimal clinical support to 
retain food intake and exercise in order to optimise patient outcome and quality of 
life.  
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Table 1: Included studies using definitive chemoradiation (dCRT) or chemotherapy in patients with esophageal cancer. 
Author(s)/ 
Reference 
number 
  
Study 
design 
Patients Treatment Response rates (%) Survival (%) 
Tepper et al 
(2008)  
[51] 
RCT phase 3 56 (SCC, AC) (1) CDDP/5-FU/50.4 Gy + SX (N = 30) 
 
 
 
 
 
(2) SX (N = 26) 
(1)  
CR 33.3 
PR 26.7 
SD 6.7 
PD 6.7 
 
(2) no data 
 
5-YR OS: 
(1)  39 (95% CI 21-
57)  
 
 
 
(2) 16 (95% CI 5-
33) 
Cooper et al 
(1999) [8] 
RCT phase 3 123 (SCC, AC) 
 
(1) CDDP/5-FU/50 Gy (N = 61):  
 
 
 
(2) 64 Gy  
(1)  
PD 26 
 
 
(2)  
PD 37 
 
5-YR OS:  
(1) 26 (95% CI 15-
37) 
 
(2) 0 
Al-Sarraf et 
al (1997) [69] 
RCT phase 3 
(update of 
RTOG 85-01 
trial) 
123 (SCC) (1) CDDP/5-FU/50 Gy (N = 61) 
 
 
(2) 64 Gy (N = 62) 
 5-YR OS: 
(1) 27 
 
(2) 0 
Wang et al 
(2006) [70] 
 
RS 35 (SCC, AC) 
 
(1) 5-FU/50.4 Gy (N = 35) 
 
CR > 50 Gy: 79.2, < 50 Gy: 
27.3 
PR 8.6 
SD 5.7 
PD 5.7 
5-YR OS: 18.6  
5-YR DFS: 22.4 
Uno et al RS 21 (SCC) (1) CDDP/5-FU/64 Gy (N = 14):  Initial LCR: 57.9 (including 5 (1) + (2) + (3)  
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1
 RTOG 85-01: CRT: CDDP 75 mg/m2 (first day of week 1, 5, 8 and 11) /5-FU 1 g/m2 (first 4 days of week 1, 5, 8 and 11) [7] 
2 FLEP: NAT: LV 300 mg/m2, VP-16 100 mg/m2, 5-FU 500 mg/m2, CDDP 30 mg/m2 on days 1-3. A 2nd and 3rd course were started at day 22 of 
the last course. CRT started between days 22 and 28 of last NAT course. CRT: CDDP 50 mg/m2 days 2 and 8, VP-16 100 mg/m2 on days 4, 5 
and 6 (60h-infusion) [8] 
(2007) [49]  
(2) CDDP/5-FU/40 Gy + SX (N = 5):  
 
(3) 64 Gy  (N = 2) 
 
SX patients) 2-YR OS: 41 
5-YR OS: 27  
Yamada et al 
(2006) [47] 
RS 27 (SCC) (1) CDDP/5-FU/66 Gy (N = 23): 
 
(2) 66 Gy  (N = 4) 
CR 48.1 
PR 40.7 
SD 11.1 
PD 0 
(1) + (2)  
5-YR OS: 37.9 
Gkika et al 
(2014) [71] 
RS 55 (SCC, AC, 
undifferentiate
d carcinoma) 
 (1) 56-70 Gy/ CDDP/5-FU (RTOG 85-
01)1 
NAT: LV/5-FU/CDDP (N = 25) 
 
(2) 56-70 Gy/ CDDP/VP-16 (FLEP)2 
NAT: 5-FU/LV/CDDP/VP-16 (N = 22) 
 
(3) 56-70 Gy/CDDP-based/irinotecan or 
taxanes (exact dose is not mentioned) (N 
= 8) 
 
CR 64 
RD 26 
PD 14.5 
PR 10.9 
3-YR OS: 
(1) 18 
 
 
(2) 37 
 
 
(3) 31 
 
Stuschke et 
al (1999) [9] 
RS 17 (SCC) 
  
(1) 60-66 Gy  
NAT: 5-FU/LV/VP-16 (FLEP)4  
CRT: CDDP/VP-16 (FLEP)4  (N = 11)  
(2) 60-66 Gy 
NAT: LV/5-FU/CDDP  
CRT: CDDP/VP-16 (FLEP)4 
2-, 3-YR 
LRR 67 + 14 
 
(1) + (2) 
2- and 3-YR  OS: 
24 
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3 No significant difference between the two regimens in terms of overall and disease-free survival.   
(N = 6) 
 
Burmeister 
et al (2000) 
[48] 
PCS 34 (SCC, AC)  (1) CDDP 80/5-FU/61.2 Gy  
(N = 24) 
(2) CDDP 20/5-FU/61.2 Gy  
(N = 8)  
(3) 5-FU/ 61.2 Gy (N =  2)  
  
CR 91.1 
PR 5.9 
SD 0 
PD 2.9 
(1) + (2) + (3) 
5-YR OS 55 (95% 
CI 38-74)3 
 
Huang et al 
(2008) [46] 
RS 50 (CEC) (1) 5-FU/mitomycin C or CDDP/54 Gy (N 
= 13) 
+ SX (N = 6)  
 
 
 
(2) CDDP/70 Gy (N = 22): 
 
 
 
 
(3) RT alone (N = 9) (dose unknown) 
(1)  
CR (1-YR) 71  
CR (2-YR) 48  
 
 
(2)  
CR (1-YR) 64  
CR (2-YR) 46  
(1) 
1-YR OS: 86 (95% 
CI 62-95) 
2-YR OS: 52 (95% 
CI 30-71)  
 
(2)  
1-YR OS: 69 (95% 
CI 49-82) 
2-YR OS: 43 (95% 
CI 24-60)  
Conroy et al 
(2014) [81] 
RCT phase 
2/3 
267 (SCC, AC, 
ASCC)  
(1) oxaliplatin/LV/5-FU (FOLFOX)/50 Gy 
(N = 134) 
 
 
 
(2) CDDP/5-FU/50 Gy (N = 133)  
 
 
(1) 
CR 44 
PR 22 
SD 11 
PD 9 
(2) 
CR 43 
PR 22 
SD 8 
3-YR OS:  
(1) 19.9 (95% CI 
10.8-31.0) 
 
 
(2) 26.9 (95% CI 
16.9-37.8)  
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4 HR: 1.53 (95% CI 1.03-2.27) (P = 0.035) 
PD 9 
 
Crosby et al 
(2013) [85] 
 
RCT phase 
2/3 
 
258 (SCC, AC)  
 
(1) CDDP/capecitabine/50 Gy (2 cycles 
CDDP/capecitabine NAT) (N = 129) 
 
(2) CDDP/capecitabine/50 Gy + 
cetuximab (2 cycles CDDP/capecitabine 
NAT) (N = 129)  
TFF at 24 weeks:  
(1) 66.4 (90% CI 58.6 ± 
73.6) 
 
(2) 76.9 (90% CI 69.7-83.0)  
 
mOS4:  
(1) 25.4 months 
(95% CI 20.5-37.9) 
 
(2) 22.1 months 
(95% CI 15.1-24.5) 
 
Ma et al 
(2011)  [76] 
RCT 102 (SCC) (1) paclitaxel/CDDP/59.4 Gy + IFI (N = 
51)  
 
 
 
(2) paclitaxel/CDDP/59.4 Gy + ENI (N = 
51) 
 
(1)  
CR (1-YR) 90.0 
CR (2-YR) 80.1 
CR (3-YR) 80.1 
 
(2)  
CR (1-YR) 92.8 
CR (2-YR) 92.8 
CR (3-YR) 85.7 
 
(1)  
1-YR OS: 100 
2-YR OS: 87.5 
3-YR OS: 32.0 
 
(2)  
1-YR OS: 100 
2-YR OS: 84.0 
3-YR OS: 41.3  
Tu et al 
(2013) [75] 
RS 36 (SCC) (1) paclitaxel/CDDP/60 Gy (IMRT) (N = 
36) 
 
CR 16.7 
PR 33.3 
SD 41.7 
 
1-YR OS: 83.3 
2-YR OS: 42.8 
 
Bleiberg et al 
(1997) [80] 
RCT phase 2 88 (SCC) (1) CTx: CDDP/5-FU (N = 44) 
prior SX (N = 5) 
prior radiotherapy (N = 4) 
 
 
 
(1)  
CR 3 
PR 32 
SD 29 
PD 18 
early death 15 
(1)  
1-YR OS: 34 (95% 
CI 20-48)  
2-YR OS: 18 (95% 
CI 7-29) 
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5 HR: 2.42 (P = 0.022)   
 
 
(2) CTx: CDDP (N = 44) 
prior SX (N = 8) 
prior radiotherapy (N = 6) 
not assessable 3 
 
(2) 
CR 3 
PR 16 
SD 38 
PD 43 
early death 0 
not assessable 0 
 
 
(2)  
1-YR OS: 27 (95% 
CI 14-40) 
2-YR OS: 9 (95% 
CI 1-17) 
Ruppert et al 
(2010) [82] 
RS 57 (SCC, AC)  (1) CDDP/irinotecan/50.4-61.2 Gy (2 
cycles CDDP/irinotecan NAT) (N = 38) 
 
 
 
 
(2) carboplatin/paclitaxel/50.4-61.2 Gy  
(N = 19) 
(1)  
CR 21.1 
 
 
 
 
(2)  
CR 31.6 
 
(1)5 
2-YR OS: 40.6 
(95% CI 26.9 ± 
61.3) 
 
 
(2)  
2-YR OS: 63.2 
(95% CI 44.8-89.0) 
 
Ludmir et al 
(2014) [40] 
RS 37 (CEC) CRT (N = 37) 
RT: 54 Gy (14.4-71) 
 
CTx: CDDP/5-FU (N = 16), CDDP (N = 
4), CDDP/VP-16 (N = 6), 
CDDP/paclitaxel (N = 6), other (N = 7) 
CR 5.6 5-YR OS: 34.1 
 
Minsky et al 
(2002)  [78] 
 
RCT phase 3 
 
236 (SCC, AC)  
 
(1) CDDP/5-FU/64.8 Gy (N = 109) 
 
(2) CDDP/5-FU/50.4 Gy (N = 109) 
 2-YR OS: 
(1) 31 
 
(2) 40 
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RCT: randomized controlled trial, SCC: squamous cell carcinoma, AC: adenocarcinoma, CDDP: cisplatin, 5-FU: 5-fluorouracil, SX: surgery, 
CR: complete response, PR: partial response, SD: stable disease, PD: progressive disease, -YR OS: -year overall survival, CI: confidence 
interval,TFF: treatment failure free, RS: retrospective study, -YR DFS: -year disease free survival, LCR: local control rate, CRT: 
chemoradiation, NAT: neoadjuvant, LV: leucovorin, VP-16: etoposide, LRR: locoregional recurrence rate, PCS: prospective cohort study, CEC: 
cervical esophageal cancer, ASCC: adenosquamous carcinoma, MOS: median overall survival, HR: hazard ratio, IFI: involved field irradiation, 
ENI: elective nodal irradiation, IMRT: intensity modulated radiation therapy, CTx: chemotherapy, LRC: locoregional control 
 
 
 
Zhang et al 
(2015) [92] 
RS 102 (CEC) CRT (N = 102) 
RT: 60 Gy (50-70) 
 
CTx:  
NAT: CDDP-based (N = 18) 
CRT:  
1. docetaxel/CDDP(N = 13) 
2. CDDP/docetaxel (N = 26) 
3. CDDP/5-FU (N = 63) 
 
 3-YR OS: 39.3 
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